Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
| Data(s) |
2002
|
|---|---|
| Identificador |
http://serval.unil.ch/?id=serval:BIB_49D46F2161CE isbn:0027-8874 (Print) pmid:12122096 isiid:000176849400007 |
| Idioma(s) |
en |
| Fonte |
Journal of the National Cancer Institute, vol. 94, no. 14, pp. 1054-1065 |
| Palavras-Chave | #Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/therapy; Chemotherapy, Adjuvant; Cyclophosphamide/administration & dosage; Endocrine System/drug effects; Fluorouracil/administration & dosage; Humans; Lymphatic Metastasis/prevention & control; Methotrexate/administration & dosage; Middle Aged; Postmenopause; Quality of Life; Tamoxifen/therapeutic use; Tamoxifen/toxicity; Time Factors; Treatment Outcome |
| Tipo |
info:eu-repo/semantics/article article |
